Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMYXR.L Regulatory News (MYXR)

  • There is currently no data for MYXR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of CFO/Grant of Share Options

16 Mar 2016 07:00

RNS Number : 2166S
MyCelx Technologies Corporation
15 March 2016
 

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

 

16 March 2016

 

 

Appointment of Chief Financial Officer

 

The Company announces that Kimberly Slayton, formerly Interim Chief Financial Officer, has been appointed as Chief Financial Officer with immediate effect.

 

 

Grant of Share Option to Chief Financial Officer

 

On 14 March 2016 Ms. Slayton was awarded the following options over the Company's common shares of US$0.025 each ("Common Shares") under the MYCELX Omnibus Performance Incentive Plan ("Plan"):

 

Name of Director

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

 

 

 

 

 

Kimberly Slayton

70,000

US$0.40*

100,000

0.53%

 

Ms. Slayton holds no Common Shares in the issued capital of the Company.

 

 

Grant of Share Option to Chief Business Development Officer

 

The Company further announces that Mark Mixon, Chief Business Development Officer, was granted an option on 14 March 2016 under the Plan over 65,000 Common Shares. The grant to Mr. Mixon was as follows:

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

 

 

 

 

 

Mark Mixon

65,000

US$0.40*

265,204

1.41%

 

In addition, following this transaction, Mr. Mixon continues to be interested in 10,000 Common Shares, representing 0.05 per cent of the present issued capital of the Company, which he holds as a custodian.

 

Following this award, Connie Mixon, Chief Executive Officer and spouse of Mr. Mixon is interested in an aggregate (including the interests of Mr. Mixon) of 991,210 Common Shares, representing 5.28 per cent of the present issued capital of the Company, and in options over an aggregate (including the interests of Mr. Mixon) of 428,221 Common Shares, representing 2.28 per cent of the present issued capital of the Company.

 

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

  

The above grants formed part of wider grants of 370,000 options to employees across the Company, on the same date, representing 1.97% of the current issued share capital.

 

The share options granted on 14 March 2016 will vest as to 50% on 31 December 2016 and 50% on 31 December 2017, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

 

*Based on the mid-market closing price of the Company's Common Shares at 11 March 2016, and the closing US/£ exchange rate at that date.

 

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kimberly Slayton, CFO

Tel: +1 888 306 6843

 

RFC Ambrian Limited

Corporate Finance

Samantha Harrison

Jonathan Stephens

 

Corporate Broking

Jonathan Williams

Kim Eckhof

 

Tel: +44 20 3440 6800

Numis Securities Limited

Corporate Broking

James Black

Ben Stoop

 

Tel: +44 20 7260 1000

 

Bell Pottinger

Nick Lambert

Henry Lerwill Tel: +44 20 3772 2500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEADDSFFAKEAF
Date   Source Headline
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
27th Sep 20172:44 pmRNSApplication for Block Admission
26th Sep 20175:31 pmRNSClosure of Restricted Stock Line
21st Sep 20177:00 amRNSConsolidation of Stock Lines
13th Sep 20177:00 amRNSHalf Year Results Statement
12th Jul 201712:30 pmRNSResult of Annual Meeting
7th Jul 20177:00 amRNSHalf Year Trading Update
9th Jun 201710:00 amRNSMailing of Annual Financial Report & GM Notice
7th Jun 201710:30 amRNSBlock listing Interim Review
30th May 20171:19 pmRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSContract win with new SABIC affiliate customer
11th May 20177:00 amRNSFinal Results for the year ending 31 December 2016
8th May 20177:00 amRNSContract Award & Notification of Full Year Results
30th Jan 20177:00 amRNSTrading Update
7th Dec 20162:34 pmRNSBlock listing Interim Review
4th Oct 20167:00 amRNSAppointment of Nominated Adviser & Broker
14th Sep 20167:00 amRNSHalf Year Results Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.